降血脂CLOFIBRATE製劑藥效調查

INVESTIGATION ON HYPOLIPIDEMIC EFFECTS OF CLOFIBRTE PREPARATIONS

於民國七十八年一月，從台灣地區藥局、藥房抽購輸入Clofibrate製劑共14廠牌20批號。以正常及以Alloxan誘發糖尿病雄性小鼠為試驗模式，評估製劑的降血脂效果：各製劑皮下注射250mg/kg/day 8日，大都能顯著降低正常小鼠的三酸甘油脂的含量；同法給與500mg/kg/day 8日，則全部都有降低三酸甘油脂的含量，且也有部分降低膽固醇的效果。但投與250mg/kg/day或500mg/kg/day各8日，對由Alloxan誘發糖尿病之雄性小鼠其膽固醇、三酸甘油脂值，則都沒有顯著地降低效果，顯示以Alloxan誘發糖尿病雄性小鼠為試驗模式，不是評估Clofibrate製劑降血脂藥效的適當方法。

Twenty samples of fourteen brands of imported clofibrate preparations werepurchased from drug stores in Taiwanarea in January 1989. Their hypolipidemic effects were investigated with normaland alloxan induced diabetic mice models. In normal mice group: administrating 250mg/Kg/day s. c. injection for 8 days, clofibrate preparations almost significantly decreased serum level of triglyceride; furthermore, administrating 500mg/Kg/day for 8 days, whole preparations significantly lowered serum level of triglyceride andpartialy lowered serum level of cholesterol. In diabetic mice group: either 250 mg/Kg/day for 8 days or 500mg/Kg/day for 8 days treatment, no clofibrate preparation could decrease serum level of triglyceride or cholesterol. Therefore, alloxan induced diabetic miceis not a good model for evaluating hypolipidemic effects of clofibrate preparations.